In the News | Friends of Cancer Research

You are here

In the News

June 3, 2019
A study that examined 10,500 health records of patients with advanced non–small cell lung cancer from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria—as... Read more
June 3, 2019
Dr R. Donald Harvey presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from a study looking at using ASCO’s CancerLinQ database to look expanding clinical trial... Read more
June 3, 2019
Only 3% of patients with cancer in the US enrol on a clinical trial – and the American Society of Clinical Oncology (ASCO) is concerned that outdated and restrictive eligibility criteria could be... Read more
June 3, 2019
Late-breaking studies featured today at this morning’s press briefing as the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting continues included the phase 3 OSLO-COMET trial, the... Read more
June 3, 2019
A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria, as... Read more
June 3, 2019
The FDA says it is making it easier for doctors to access unapproved therapies for cancer patients, but Richard Padzur, MD, is emphatic: the pilot program, called Project Facilitate, only covers... Read more
June 3, 2019
It may be possible to double the number of patients eligible for clinical trials for advanced non–small-cell lung cancer (NSCLC). A study looking at 10,500 health records of advanced NSCLC patients... Read more
June 3, 2019
The FDA has unveiled what it describes as a pilot “concierge service” for oncologists and patients seeking information and assistance with expanded access (EA) to investigational therapies. The two-... Read more
June 3, 2019
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with... Read more
May 31, 2019
While PD-L1 testing has become commonplace with immuno-oncology treatment, the multitude of available antibodies, cut-offs, and scoring algorithms makes this biomarker anything but uniform and... Read more

Pages